Publications
349 results found
Arasi S, Nurmatov U, Dunn-Galvin A, et al., 2023, WAO consensus on DEfinition of Food Allergy SEverity (DEFASE)., World Allergy Organ J, Vol: 16, ISSN: 1939-4551
BACKGROUND: While several scoring systems for the severity of anaphylactic reactions have been developed, there is a lack of consensus on definition and categorisation of severity of food allergy disease as a whole. AIM: To develop an international consensus on the severity of food allergy (DEfinition of Food Allergy Severity, DEFASE) scoring system, to be used globally. METHODS PHASE 1: We conducted a mixed-method systematic review (SR) of 11 databases for published and unpublished literature on severity of food allergy management and set up a panel of international experts. PHASE 2: Based on our findings in Phase 1, we drafted statements for a two-round modified electronic Delphi (e-Delphi) survey. A purposefully selected multidisciplinary international expert panel on food allergy (n = 60) was identified and sent a structured questionnaire, including a set of statements on different domains of food allergy severity related to symptoms, health-related quality of life, and economic impact. Participants were asked to score their agreement on each statement on a 5-point Likert scale ranging from "strongly agree" to "strongly disagree". Median scores and percentage agreements were calculated. Consensus was defined a priori as being achieved if 70% or more of panel members rated a statement as "strongly agree" to "agree" after the second round. Based on feedback, 2 additional online voting rounds were conducted. RESULTS: We received responses from 92% of Delphi panel members in round 1 and 85% in round 2. Consensus was achieved on the overall score and in all of the 5 specific key domains as essential components of the DEFASE score. CONCLUSIONS: The DEFASE score is the first comprehensive grading of food allergy severity that considers not only the severity of a single reaction, but the whole disease spectrum. An international consensus has been achieved regarding a scoring system for food allergy disease. It offers an
Boyle RJ, Flohr C, Shamji MH, 2023, Global trends in eczema prevalence during early life., Clin Exp Allergy, Vol: 53, Pages: 252-254
Munblit D, Petrou L, Boyle R, 2023, Health and nutrition claims for infant formula: international cross sectional survey, BMJ: British Medical Journal, Vol: 380, Pages: 1-10, ISSN: 0959-535X
Objectives To review available health and nutrition claims for infant formula products in multiple countries and to evaluate the validity of the evidence used for substantiation of claims.Design International cross sectional survey.Setting Public facing and healthcare professional facing company owned or company managed formula industry websites providing information about products marketed for healthy infants delivered at full term in 15 countries: Australia, Canada, Germany, India, Italy, Japan, Nigeria, Norway, Pakistan, Russia, Saudi Arabia, South Africa, Spain, the United Kingdom, and the United States in 2020-22.Main outcome measures Number and type of claims made for each product and ingredient. References cited were reviewed and risk of bias was assessed for registered clinical trials using the Cochrane risk of bias tool, and for systematic reviews using the Risk Of Bias in Systematic reviews tool.Results 757 infant formula products were identified, each with a median of two claims (range from 1 (Australia) to 4 (US)), and 31 types of claims across all products. Of 608 products with ≥1 claims, the most common claim types were “helps/supports development of brain and/or eyes and/or nervous system” (323 (53%) products, 13 ingredients), “strengthens/supports a healthy immune system” (239 (39%) products, 12 ingredients), and “helps/supports growth and development” (224 (37%) products, 20 ingredients). 41 groups of ingredients were associated with ≥1claims, but many claims were made without reference to a specific ingredient (307 (50%) products). The most common groups of ingredients cited in claims were long chain polyunsaturated fatty acids (278 (46%) products, 9 different claims); prebiotics, probiotics, or synbiotics (225 (37%) products, 19 claims); and hydrolysed protein (120 (20%) products, 9 claims). 161/608 (26%) products with ≥1 claims provided a scientific reference to support the claim—266 unique refer
Lloyd M, Loke P, Mack DP, et al., 2023, Varying Approaches to Management of IgE-Mediated Food Allergy in Children Around the World., J Allergy Clin Immunol Pract
Food allergy is a chronic disease that affects individuals of all ages and is a significant public health problem globally. This narrative overview examines clinical management strategies for IgE-mediated food allergy in children around the world to understand variations in practice. Information was drawn from clinical practice guidelines, recent research, the websites of professional and governmental bodies with expertise in food allergy, and clinical experts from a broad cross-section of geographical regions. The structure and delivery of clinical services, allergen avoidance and food labeling, and resources to support the management of allergic reactions in the community are discussed in detail. The adoption of emerging food immunotherapies is also explored. Wide variations in clinical management of food allergy were apparent across the different countries. Common themes were continuing issues with access to specialist care and recognition of the need to balance risk reduction with dietary and social restrictions to avoid unnecessary detrimental impacts on the quality of life of food allergy sufferers. Findings highlight the need for standardized presentation of practice and priorities, and may assist clinicians and researchers when engaging with government and funding agencies to address gaps.
Shamji MH, Boyle RJ, 2023, Biological therapy practice, biomarkers of severe asthma and novel approaches for attaining immunomodulation in upper airway disease., Clin Exp Allergy, Vol: 53, Pages: 130-131
The hybrid rDer p 2231 stimulated in PBMCs isolated from atopic patients, higher levels of IL-2, IL-10, IL-15 and IFN-γ, as well as lower levels of IL-4, IL-5, IL-13, TNF-α and GM-CSF. The use of hybrid molecules as a therapeutic model in D. pteronyssinus allergic mice led to the reduction of IgE production and lower eosinophilic peroxidase activity in the airways. We found increased levels of IgG antibodies, which blocked the IgE binding to the parental allergens in serum of atopic patients. Furthermore, the stimulation of splenocytes from mice treated with rDer p 2231 induced higher levels of IL-10 and IFN-γ and decreased the secretion of IL-4 and IL-5, when compared to parental allergens and D. pteronyssinus extract. (7).
Boyle R, 2023, Timing of allergenic food introduction and risk of IgE-mediated food allergy: systematic review and meta-analysis, JAMA Pediatrics, ISSN: 1072-4710
Boyle RJ, Shamji MH, 2023, What does Clinical and Experimental Allergy mean by Trusted Evidence in Allergy'?, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 53, Pages: 4-6, ISSN: 0954-7894
Shamji MH, Boyle RJ, 2022, Mepolizumab for eosinophilic chronic rhinosinusitis, loss of smell and challenges with accessibility to allergen immunotherapy, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 1358-1360, ISSN: 0954-7894
Kelleher MM, Phillips R, Brown SJ, et al., 2022, Skin care interventions in infants for preventing eczema and food allergy., Cochrane Database Syst Rev, Vol: 11
BACKGROUND: Eczema and food allergy are common health conditions that usually begin in early childhood and often occur in the same people. They can be associated with an impaired skin barrier in early infancy. It is unclear whether trying to prevent or reverse an impaired skin barrier soon after birth is effective for preventing eczema or food allergy. OBJECTIVES: Primary objective To assess the effects of skin care interventions such as emollients for primary prevention of eczema and food allergy in infants. Secondary objective To identify features of study populations such as age, hereditary risk, and adherence to interventions that are associated with the greatest treatment benefit or harm for both eczema and food allergy. SEARCH METHODS: We performed an updated search of the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, and Embase in September 2021. We searched two trials registers in July 2021. We checked the reference lists of included studies and relevant systematic reviews, and scanned conference proceedings to identify further references to relevant randomised controlled trials (RCTs). SELECTION CRITERIA: We included RCTs of skin care interventions that could potentially enhance skin barrier function, reduce dryness, or reduce subclinical inflammation in healthy term (> 37 weeks) infants (≤ 12 months) without pre-existing eczema, food allergy, or other skin condition. Eligible comparisons were standard care in the locality or no treatment. Types of skin care interventions could include moisturisers/emollients; bathing products; advice regarding reducing soap exposure and bathing frequency; and use of water softeners. No minimum follow-up was required. DATA COLLECTION AND ANALYSIS: This is a prospective individual participant data (IPD) meta-analysis. We used standard Cochrane methodological procedures, and primary analyses used the IPD dataset. Primary outcomes wer
Bradshaw LE, Wyatt LA, Brown SJ, et al., 2022, Emollients for prevention of atopic dermatitis: 5-year findings from the BEEP randomized trial, ALLERGY, ISSN: 0105-4538
Boyle RJ, Shamji MH, 2022, Are paediatric allergy services promoting or harming public health?, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 1238-1240, ISSN: 0954-7894
Shamji MH, Boyle RJ, 2022, Immunophenotyping and leukocyte redistribution in corticosteroid resistant severe asthma, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 1126-1128, ISSN: 0954-7894
Banerjee J, McLister A, Gourin B, et al., 2022, Tributyrin ester-impregnated pH strips for confirming neonatal feeding tube placement: a diagnostic test accuracy study, Archives of Disease in Childhood: Fetal and Neonatal Edition, ISSN: 1359-2998
Boyle RJ, Munblit D, Shamji MH, 2022, Patient-oriented allergy, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 1012-1014, ISSN: 0954-7894
Dua S, Ruiz-Garcia M, Bond S, et al., 2022, Effects of Exercise and Sleep Deprivation on Reaction Severity During Oral Peanut Challenge: A Randomized Controlled Trial, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, Vol: 10, Pages: 2404-+, ISSN: 2213-2198
- Author Web Link
- Cite
- Citations: 1
Mehta S, Allen H, Campbell D, et al., 2022, Trends in use of specialized formula for managing cow's milk allergy in young children, Joint Conference of the British-Society-for-Allergy-and-Immunology (BSACI) and World-Allergy-Organization (WAO), Publisher: WILEY, Pages: 1053-1053, ISSN: 0954-7894
Shamji MH, Boyle RJ, 2022, Immune modulation an COVID 19 in the Asia-Pacific region, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 922-923, ISSN: 0954-7894
Allen H, Pendower U, Santer M, et al., 2022, An international Delphi consensus study on the detection and management of milk allergy, Publisher: WILEY, Pages: 1043-1044, ISSN: 0954-7894
Jackson E, Allen H, Bradshaw L, et al., 2022, Prevalence and pattern of milk allergy overdiagnosis in the BEEP trial population, Publisher: WILEY, Pages: 1067-1068, ISSN: 0954-7894
Steele L, Stuart B, Axon E, et al., 2022, Topical anti-inflammatory treatments for eczema: network meta-analysis, Cochrane Database of Systematic Reviews, Vol: 2022, ISSN: 1465-1858
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To compare the efficacy and safety of topical anti-inflammatory treatments for reducing eczema symptoms or signs or improving eczema-related quality of life in children and adults with eczema, by undertaking a network meta-analysis. To provide a clinically useful ranking of these treatments according to their efficacy and safety.
Mehta S, Allen HI, Campbell DE, et al., 2022, Trends in use of specialised formula for managing cow’s milk allergy in young children, Clinical and Experimental Allergy, Vol: 52, Pages: 839-847, ISSN: 0954-7894
Background:Excessive use of specialised formula for cow’s milk allergy was reported in England, but complete analysis has not been undertaken and trends in other countries are unknown. Some specialised formula products, especially amino-acid formula, have high free sugars content. We evaluated specialised formula trends in countries with public databases documenting national prescription rates.Methods:Cross-sectional analysis of national prescription databases in United Kingdom, Norway and Australia. Outcomes were volume and cost of specialised formula, and proportion of infants prescribed specialised formula. Expected volumes assumed 1% cow’s milk allergy incidence and similar formula feeding rates between infants with and without milk allergy.Results:Prescribed volumes of specialised formula for infants rose 2.8-fold in England from 2007-2018, with similar trends in other regions of the United Kingdom. Volumes rose 2.2-fold in Norway from 2009-2020 and 3.2-fold in Australia from 2001-2012. In 2020, total volumes were 9.7 to 12.6-fold greater than expected in England, 8.3 to 15.6-fold greater than expected in Norway and 3.3 to 4.5-fold greater than expected in Australia, where prescribing restrictions were introduced in 2012. In Norway the proportion of infants prescribed specialised formula increased from 2.2% in 2009 to 6.9% in 2020, or 11.2 to 13.3-fold greater than expected. In 2020, specialised formula for infants cost US$117 (103 euro) per birth in England, US$93 (82 euro) in Norway and US$27 (23 euro) in Australia. Soya formula prescriptions exceeded expected volumes 5.5 to 6.4-fold in England in 1994 and subsequently declined, co-incident with public health concerns regarding soya formula safety. In 2020, 30-50% of prescribed specialised formula across the three countries was amino-acid formula.Conclusions:In England, Norway and Australia, specialised formula prescriptions increased in the early 21st century and exceeded expected levels. Unneces
Shamji MH, Boyle RJ, Roberts G, 2022, Prize-winning abstracts from BSACI/WAO 2022 meeting, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 830-832, ISSN: 0954-7894
Boyle RJ, Shamji MH, 2022, Clinical and Experimental Allergy boycotts formula advertising, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 828-829, ISSN: 0954-7894
Allen HI, Pendower U, Santer M, et al., 2022, Detection and management of milk allergy: Delphi consensus study, Clinical & Experimental Allergy, Vol: 52, Pages: 848-858, ISSN: 0954-7894
BackgroundThere is significant overdiagnosis of milk allergy in young children in some countries, leading to unnecessary use of specialised formula. This guidance, developed by experts without commercial ties to the formula industry, aims to reduce milk allergy overdiagnosis and support carers of children with suspected milk allergy.MethodsDelphi study involving two rounds of anonymous consensus building and an open meeting between January and July 2021. Seventeen experts in general practice, nutrition, midwifery, health visiting, lactation support and relevant areas of paediatrics participated, located in Europe, North America, Middle East, Africa, Australia, and Asia. Five authors of previous milk allergy guidelines and seven parents provided feedback.FindingsParticipants agreed on 38 essential recommendations through consensus. Recommendations highlighted the importance of reproducibility and specificity for diagnosing milk allergy in children with acute or delayed symptoms temporally related to milk protein ingestion; and distinguished between children directly consuming milk protein and exclusively breastfed infants. Consensus was reached that maternal dietary restriction is not usually necessary to manage milk allergy, and that for exclusively breastfed infants with chronic symptoms, milk allergy diagnosis should only be considered in specific, rare circumstances. Consensus was reached that milk allergy diagnosis does not need to be considered for stool changes, aversive feeding, or occasional spots of blood in stool, if there is no temporal relationship with milk protein ingestion. When compared with previous guidelines, these consensus recommendations resulted in more restrictive criteria for detecting milk allergy and a more limited role for maternal dietary exclusions and specialised formula.InterpretationThese new milk allergy recommendations from non-conflicted, multidisciplinary experts advise narrower criteria, more prominent support for breastfeeding
Kelleher MM, Cro S, Phillips R, et al., 2022, Correspondence to " Emollients in infancy to prevent atopic dermatitis: A systematic review and meta-analysis", ALLERGY, Vol: 77, Pages: 1931-1933, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 1
Shamji MH, Boyle RJ, 2022, Biomarkers of airway inflammation and immunotherapy, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 726-728, ISSN: 0954-7894
Trayer J, Rowbotham NJ, Boyle RJ, et al., 2022, Industry influence in healthcare harms patients: myth or maxim?, BREATHE, Vol: 18, ISSN: 1810-6838
- Author Web Link
- Cite
- Citations: 1
Gorman E, Shankar-Hari M, Hopkins P, et al., 2022, Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo- controlled phase 2 trial, TRIALS, Vol: 23
Gamirova A, Berbenyuk A, Levina D, et al., 2022, Food Proteins in Human Breast Milk and Probability of IgE-Mediated Allergic Reaction in Children During Breastfeeding: A Systematic Review, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, Vol: 10, Pages: 1312-+, ISSN: 2213-2198
- Author Web Link
- Cite
- Citations: 4
Boyle RJ, Shamji MH, 2022, Early origins of allergic disease, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 52, Pages: 592-594, ISSN: 0954-7894
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.